State of Michigan Retirement System Sells 200 Shares of Hologic, Inc. (NASDAQ:HOLX)

State of Michigan Retirement System lowered its position in Hologic, Inc. (NASDAQ:HOLX) by 0.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 63,065 shares of the medical equipment provider’s stock after selling 200 shares during the quarter. State of Michigan Retirement System’s holdings in Hologic were worth $4,546,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. General Partner Inc. purchased a new stake in Hologic in the 4th quarter worth about $26,000. Venturi Wealth Management LLC raised its holdings in shares of Hologic by 156.3% in the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 261 shares during the period. First Horizon Advisors Inc. lifted its stake in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 159 shares during the period. Finally, Covestor Ltd grew its position in Hologic by 23.8% in the 3rd quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after acquiring an additional 133 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on HOLX shares. Wolfe Research assumed coverage on shares of Hologic in a research report on Friday, December 13th. They set a “peer perform” rating on the stock. Raymond James reiterated an “outperform” rating and set a $90.00 target price (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. Leerink Partnrs lowered shares of Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Needham & Company LLC downgraded shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective on the stock. in a research note on Monday, February 3rd. Finally, StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $84.62.

Hologic Stock Up 0.7 %

Shares of HOLX stock opened at $62.50 on Friday. The stock’s fifty day moving average price is $68.56 and its 200 day moving average price is $75.55. Hologic, Inc. has a 1-year low of $61.70 and a 1-year high of $84.67. The company has a market cap of $14.02 billion, a price-to-earnings ratio of 19.72, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.